BR112012024059A2 - processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco - Google Patents

processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco

Info

Publication number
BR112012024059A2
BR112012024059A2 BR112012024059A BR112012024059A BR112012024059A2 BR 112012024059 A2 BR112012024059 A2 BR 112012024059A2 BR 112012024059 A BR112012024059 A BR 112012024059A BR 112012024059 A BR112012024059 A BR 112012024059A BR 112012024059 A2 BR112012024059 A2 BR 112012024059A2
Authority
BR
Brazil
Prior art keywords
dry powder
inhalation
pharmaceutical
excipient
preparing
Prior art date
Application number
BR112012024059A
Other languages
English (en)
Other versions
BR112012024059B1 (pt
Inventor
Alain Chamayou
Daniela Cocconi
Laurence Galet
Rossella Musa
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42790618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012024059(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of BR112012024059A2 publication Critical patent/BR112012024059A2/pt
Publication of BR112012024059B1 publication Critical patent/BR112012024059B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112012024059-5A 2010-04-01 2011-03-11 Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco BR112012024059B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10158951.3 2010-04-01
EP10158951 2010-04-01
PCT/EP2011/053695 WO2011120779A1 (en) 2010-04-01 2011-03-11 Process for preparing carrier particles for dry powders for inhalation

Publications (2)

Publication Number Publication Date
BR112012024059A2 true BR112012024059A2 (pt) 2016-08-30
BR112012024059B1 BR112012024059B1 (pt) 2021-06-01

Family

ID=42790618

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024059-5A BR112012024059B1 (pt) 2010-04-01 2011-03-11 Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco

Country Status (21)

Country Link
US (3) US8974831B2 (pt)
EP (2) EP2762133A1 (pt)
JP (2) JP5927175B2 (pt)
KR (1) KR101730684B1 (pt)
CN (2) CN102858326A (pt)
AR (1) AR080747A1 (pt)
AU (1) AU2011234751B2 (pt)
BR (1) BR112012024059B1 (pt)
CA (1) CA2794941C (pt)
ES (1) ES2675575T3 (pt)
HK (1) HK1204569A1 (pt)
IL (1) IL222154A (pt)
MX (1) MX336414B (pt)
MY (1) MY162391A (pt)
PL (1) PL2552424T3 (pt)
RU (1) RU2585101C2 (pt)
SG (1) SG184352A1 (pt)
TR (1) TR201811349T4 (pt)
TW (1) TWI491417B (pt)
UA (1) UA110106C2 (pt)
WO (1) WO2011120779A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
LT2435025T (lt) 2009-05-29 2016-09-26 Pearl Therapeutics, Inc. Veikliosios medžiagos tiekimas per kvėpavimo takus
EP2806855B1 (en) 2012-01-25 2018-07-11 Chiesi Farmaceutici S.p.A. Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
EP2666465A1 (en) * 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
JP2016504358A (ja) * 2012-12-27 2016-02-12 マイクロドース セラピューテクス，インコーポレイテッド オキシブチニンを投与するための方法および組成物
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
RS61652B1 (sr) * 2013-07-11 2021-04-29 Chiesi Farm Spa Formulacija suvog praha koja obuhvata antiholinergijski agens, kortikosteroid i beta-adrenergik za primenu inhalacijom
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
DK2897589T3 (en) * 2013-11-22 2018-03-12 Teva Branded Pharmaceutical Prod R & D Inc Inhalable drug
UA115958C2 (uk) * 2014-09-09 2018-01-10 Вектура Лімітед Препарат, що містить глікопіролат, спосіб та пристрій
WO2016067252A1 (en) 2014-10-31 2016-05-06 Glaxosmithkline Intellectual Property Development Limited Powder formulation
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
KR20160117069A (ko) * 2015-03-31 2016-10-10 한미약품 주식회사 복합 활성성분의 안정성이 개선된 흡입용 캡슐제
CN105012278B (zh) * 2015-08-04 2017-12-29 广东省生物工程研究所（广州甘蔗糖业研究所） 一种干粉吸入粉雾剂载体蔗糖及其制备方法
CN107569474A (zh) * 2016-07-04 2018-01-12 正大天晴药业集团股份有限公司 一种可吸入干粉形式的药物组合物所用的载体的制备方法
TWI745396B (zh) * 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
WO2019067708A1 (en) * 2017-09-27 2019-04-04 Teva Branded Pharmaceutical Products R&D, Inc. METHOD FOR DECREASING PARTICLE SIZE
CA3086820A1 (en) * 2017-12-28 2019-07-04 Sumitomo Dainippon Pharma Co., Ltd. Novel fine particle coating (drug-containing hollow particle and method for manufacturing same)
JP7239604B2 (ja) 2018-04-16 2023-03-14 ツェティ，ユリア 甲状腺ホルモンを含む吸入用の薬学的乾燥粉末組成物
PL3833964T3 (pl) * 2018-08-07 2023-09-04 Norton (Waterford) Limited Zastosowanie spektroskopii ramana do produkcji proszków do inhalacji
CN109745564A (zh) * 2019-01-28 2019-05-14 上海方予健康医药科技有限公司 一种吸入干粉组合物的制备方法
KR102669919B1 (ko) * 2019-07-10 2024-05-28 한미약품 주식회사 흡입용 캡슐제 및 이의 제조방법
AU2020356243A1 (en) 2019-09-24 2022-03-24 Chiesi Farmaceutici S.P.A. Novel carrier particles for dry powder formulations for inhalation
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
EP4196105A1 (en) 2020-08-14 2023-06-21 Norton (Waterford) Limited An inhalable formulation of fluticasone propionate and albuterol sulfate
WO2022045995A1 (en) * 2020-08-28 2022-03-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
WO2023069028A1 (en) * 2021-10-20 2023-04-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
WO2024062007A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024133905A1 (de) 2022-12-22 2024-06-27 Stada Arzneimittel Ag Pharmazeutische zusammensetzung zur behandlung von copd

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT347054B (de) 1973-09-29 1978-12-11 Takeda Chemical Industries Ltd Verfahren zur herstellung von neuen nonapeptidamid-derivaten
BE847762A (fr) 1975-10-29 1977-02-14 Nouveaux nonapeptides et procedes pour les preparer,
US4124577A (en) 1977-06-13 1978-11-07 Warner-Lambert Nonapeptides and methods for their production
US4317815A (en) 1979-06-13 1982-03-02 Coy David Howard LH-RH Antagonists
US5110904A (en) 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
NZ511527A (en) * 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
IT1309592B1 (it) 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
BR9917246A (pt) * 1999-03-05 2002-03-26 Chiesi Farma Spa Composições farmacêuticas avançadas em pó para inalação
ITMI991582A1 (it) * 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
DK2283818T3 (en) * 2000-11-30 2017-10-16 Vectura Ltd Process for preparing particles for use in a pharmaceutical composition
DE60239639D1 (de) 2002-07-31 2011-05-12 Chiesi Farma Spa Pulverinhalator
JP2006507036A (ja) * 2002-08-14 2006-03-02 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 薬剤粒子のコーティング方法
CA2516733C (en) 2003-02-21 2011-09-27 The University Of Bath Process for the production of particles
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
GB0705159D0 (en) 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
GB0711680D0 (en) 2007-06-18 2007-07-25 Prosonix Ltd Process
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
AU2008325290B2 (en) 2007-11-07 2011-12-08 Astrazeneca Ab Dry powder formulations comprising ascorbic acid derivates
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
CN102149437B (zh) 2008-07-18 2017-02-15 普罗索尼克斯有限公司 用于提高氟替卡松颗粒结晶度的方法
KR20140005150A (ko) 2010-09-30 2014-01-14 키에시 파르마슈티시 엣스. 피. 에이. 흡입용 건조 분말 제제 내 마그네슘 스테아레이트의 용도

Also Published As

Publication number Publication date
JP2013523670A (ja) 2013-06-17
SG184352A1 (en) 2012-10-30
JP6162181B2 (ja) 2017-07-12
ES2675575T3 (es) 2018-07-11
AR080747A1 (es) 2012-05-02
KR101730684B1 (ko) 2017-04-26
AU2011234751A1 (en) 2012-10-25
HK1204569A1 (en) 2015-11-27
CN104257610A (zh) 2015-01-07
US20110262547A1 (en) 2011-10-27
TR201811349T4 (tr) 2018-09-21
TWI491417B (zh) 2015-07-11
CA2794941C (en) 2018-05-15
TW201200163A (en) 2012-01-01
EP2552424A1 (en) 2013-02-06
MY162391A (en) 2017-06-15
CN102858326A (zh) 2013-01-02
MX2012010914A (es) 2012-10-10
CA2794941A1 (en) 2011-10-06
EP2762133A1 (en) 2014-08-06
EP2552424B1 (en) 2018-05-09
US20150202159A1 (en) 2015-07-23
BR112012024059B1 (pt) 2021-06-01
UA110106C2 (uk) 2015-11-25
WO2011120779A1 (en) 2011-10-06
RU2012142295A (ru) 2014-05-10
US8974831B2 (en) 2015-03-10
US20160354314A1 (en) 2016-12-08
US9445999B2 (en) 2016-09-20
JP2015172097A (ja) 2015-10-01
IL222154A (en) 2016-02-29
MX336414B (es) 2016-01-19
KR20130029760A (ko) 2013-03-25
AU2011234751B2 (en) 2016-03-17
PL2552424T3 (pl) 2018-10-31
RU2585101C2 (ru) 2016-05-27
JP5927175B2 (ja) 2016-06-01

Similar Documents

Publication Publication Date Title
BR112012024059A2 (pt) processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco
BR112012026804A2 (pt) processo para preparar partículas carreadoras de uma formulação em pó seco para inalação, processo para preparar uma formulação em pó seco para inalaçao, mistura de partículas do co-micronizadas, formulação em pó seco, inalador de pó seco e uso de uma mistura de partículas co-micronizadas
IL257518B (en) Integrin agonist compounds and medicinal compositions thereof
BR112015004418A2 (pt) composição de pó seco inalável, sistema de liberação de fármaco, processo para formar uma partícula e kit.
IL233663A0 (en) New indolizine compounds, a process for their preparation and pharmaceutical preparations containing them
IL230010B (en) Inhalable pharmaceutical ingredients
IL225640A (en) Benzimidazole Derivatives, Pharmaceutical Preparations Containing Them, Processes for their Preparation and Uses as Respiratory Systemic Viral Inhibitors
IL231009A (en) The heterotromatic compounds in the oak, their preparation and their pharmaceutical preparations
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
HUP1000069A2 (en) New salts for the preparation of pharmaceutical composition
ZA201207634B (en) Pharmaceutical powder composition for inhalation
SG11201400580VA (en) Pharmaceutical composition for inhalation
EP2702054A4 (en) NOVEL BISAMINOQUINOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM, AND USE THEREOF
IL232035A (en) These heterocyclic compounds, these compounds as a medicine and a pharmaceutical composition containing them
BR112014025518A2 (pt) partículas agregadas, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de um estearato de magnésio em partículas agregadas
BR112014017481A2 (pt) formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação
BR112014013354A2 (pt) processo para a preparação de um polímero, composição, composto, e, formulação
IL232577A (en) History of morpholinylbenzotriazine, their preparation and their pharmaceutical preparations
EP2618816A4 (en) AEROSOL COMPOSITION FOR THE ADMINISTRATION OF MEDICAMENTS
HRP20141240T1 (en) An inhalable pharmaceutical composition
IL230219B (en) History of dihydropyrazole, their preparation and pharmaceutical preparations containing them
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
EP2666482A4 (en) PARTICLE COMPOSITION AND PHARMACEUTICAL COMPOSITION WITH PARTICLE COMPOSITION
ZA201104910B (en) Dry powder pharmaceutical composition for inhalation
PL2729207T3 (pl) Inhalator suchego proszku

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF